Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting
With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 9, 2022, approved the following along with other business matters. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Tuesday, May 10, 2022 at 12:00 Noon IST to discuss the Audited Financial Results for the Q4 & FY22, to be declared on May 09, 2022. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Corporate Action-Board to consider Dividend
With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 9th May, 2022 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2022. 2) To consider declaration of Interim Dividend, if any, for the financial year 2021-22 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 17th May, 2022, if considered and approved by the Board. Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The 9Th May, 2022
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2022 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 9th May, 2022 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2022. 2) To consider declaration of Interim Dividend, if any, for the financial year 2021-22 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 17th May, 2022, if considered and approved by the Board. Suven Pharmaceuticals Ltd - 543064 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySuven Pharmaceuticals Ltd 2CINL24299TG2018PLC128171 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 48.44 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: K HANUMANTHA RAO Designation: Company Secretary EmailId: khrao@suvenpharm.com Name of the Chief Financial Officer: P SUBBA RAO Designation: Chief Financial Officer EmailId: psrao@suvenpharm.com Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on April 23, 2022. Facilities Rating Long-term Bank Facilities CRISIL A+/Stable (Upgraded from 'CRISIL A/Stable') Short-term Bank Facilities CRISIL A1+ (Upgraded from 'CRISIL A1') This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Year Ended 31St March, 2022
With reference to above subject, please find enclosed Compliance Certificate for the year ended 31st March, 2022 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2022
With reference to the above subject, please find enclosed compliance certificate for the year ended 31st March, 2022 duly signed by the Compliance Officer and authorised representative of the Share Transfer Agent (KFin Technologies Limited, Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Acquisition
With reference to the above subject, in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Suven Pharmaceuticals Limited (SPL) in its meeting held today i.e., 5th April, 2022 at 10.30 a.m. has approved the investments by way of purchase of entire (100%) share capital from the existing shareholders of Casper Pharma Private Limited ('CPPL') a Hyderabad based SEZ company engaged in formulations business. Post purchase of shares, the target entity would become a wholly owned subsidiary of SPL. We provide the disclosures with respect to the above as under: